AlphaQuest LLC Trims Stock Position in Medpace Holdings, Inc. $MEDP

AlphaQuest LLC decreased its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 78.7% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 484 shares of the company’s stock after selling 1,785 shares during the period. AlphaQuest LLC’s holdings in Medpace were worth $249,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of MEDP. Fifth Third Wealth Advisors LLC lifted its position in Medpace by 2.6% in the third quarter. Fifth Third Wealth Advisors LLC now owns 737 shares of the company’s stock valued at $379,000 after acquiring an additional 19 shares during the last quarter. Portside Wealth Group LLC increased its position in shares of Medpace by 2.5% during the second quarter. Portside Wealth Group LLC now owns 1,090 shares of the company’s stock worth $342,000 after purchasing an additional 27 shares in the last quarter. Whittier Trust Co. of Nevada Inc. lifted its holdings in shares of Medpace by 35.1% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 104 shares of the company’s stock valued at $55,000 after purchasing an additional 27 shares during the last quarter. M&T Bank Corp boosted its position in shares of Medpace by 3.4% in the 2nd quarter. M&T Bank Corp now owns 939 shares of the company’s stock valued at $295,000 after purchasing an additional 31 shares during the period. Finally, Front Row Advisors LLC grew its stake in Medpace by 0.4% during the 2nd quarter. Front Row Advisors LLC now owns 9,441 shares of the company’s stock worth $2,963,000 after buying an additional 35 shares during the last quarter. 77.98% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms have commented on MEDP. Robert W. Baird set a $613.00 price target on Medpace in a research report on Friday, October 24th. Wall Street Zen raised shares of Medpace from a “hold” rating to a “buy” rating in a report on Saturday, January 17th. Zacks Research cut shares of Medpace from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 12th. Weiss Ratings reissued a “buy (b)” rating on shares of Medpace in a research report on Wednesday, January 28th. Finally, Truist Financial set a $555.00 target price on shares of Medpace in a report on Monday, October 27th. Two research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Reduce” and a consensus target price of $491.27.

Medpace Price Performance

NASDAQ:MEDP opened at $530.35 on Tuesday. The firm’s fifty day moving average price is $578.30 and its 200 day moving average price is $539.57. Medpace Holdings, Inc. has a 1-year low of $250.05 and a 1-year high of $628.92. The firm has a market cap of $14.94 billion, a price-to-earnings ratio of 37.09, a price-to-earnings-growth ratio of 1.82 and a beta of 1.42.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Monday, February 9th. The company reported $4.67 EPS for the quarter, topping analysts’ consensus estimates of $4.18 by $0.49. Medpace had a net margin of 18.36% and a return on equity of 91.88%. The company had revenue of $708.45 million during the quarter, compared to the consensus estimate of $689.53 million. During the same quarter in the prior year, the firm earned $3.67 EPS. Medpace’s quarterly revenue was up 32.0% on a year-over-year basis. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, analysts expect that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Insider Activity

In other news, VP Susan E. Burwig sold 20,000 shares of the stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $609.15, for a total transaction of $12,183,000.00. Following the completion of the transaction, the vice president directly owned 27,500 shares of the company’s stock, valued at approximately $16,751,625. This represents a 42.11% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO August J. Troendle sold 59,025 shares of the firm’s stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $607.78, for a total value of $35,874,214.50. Following the completion of the sale, the chief executive officer directly owned 774,602 shares of the company’s stock, valued at $470,787,603.56. This represents a 7.08% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 302,192 shares of company stock valued at $182,019,762 over the last three months. 20.30% of the stock is currently owned by corporate insiders.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.